Strategic Report on Inflammatory Bowel Disease Treatment Market: Growth Opportunities and Emerging Challenges
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What CAGR Is Anticipated for the Inflammatory Bowel Disease Treatment Market Through 2029?
In recent years, the market size for the treatment of inflammatory bowel disease has witnessed a robust growth. This market is forecasted to expand from $25.26 billion in 2024 to $27.19 billion in 2025, showcasing a compound annual growth rate (CAGR) of 7.6%. The upturn during the historical period can be credited to factors such as the increasing occurrence of inflammatory bowel disease, growing preference for biologics and immunomodulators, advancements in treatment methodology, an escalating older population, and a heightened consciousness about the disease.
In the coming years, the market for inflammatory bowel disease (IBD) treatment is projected to experience significant growth, with potential to reach “$39.39 billion in 2029 at a compound annual growth rate (CAGR) of 9.7%.” Factors driving this projected growth include increased investment in R&D efforts, higher demand for biosimilars, an increasing prevalence of IBD in developing markets, the rising need for tailor-made medicine, and the incorporation of precision medicine in IBD care. A rise in product introductions and approvals, individualized dosage and treatment strategies in managing IBD, the application of telemedicine in remotely tracking IBD patients, the investigation of microbiome-oriented therapies for IBD, and the implementation of value-based care models in IBD management are also potential trends for the forecast period.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=6704&type=smp
What Market Forces Are Driving The Inflammatory Bowel Disease Treatment Sector In 2025 And Beyond?
The inflammatory bowel disease treatment market is witnessing significant growth due to the increasing incidence of Crohn’s disease and ulcerative colitis. These disorders, both subtypes of inflammatory bowel disease (IBD), cause inflammation and sores or ulcers in the digestive tract. The increasing instances of these conditions are set to heighten demand for treatments designed to alleviate bowel inflammation and curb potential medical complications. March 2022 research sourced from the United States National Library of Medicine, a medical library based in the US, indicates that approximately 1.6 million Americans are presently living with an inflammatory bowel disease (either Crohn’s disease or ulcerative colitis). Also, about 70,000 fresh IBD cases are identified annually within the US. Therefore, the escalating occurrence of Crohn’s disease and ulcerative colitis will likely fuel the growth of the inflammatory bowel disease treatment market.
How Is The Global Inflammatory Bowel Disease Treatment Market Categorized By Segments?
The inflammatory bowel disease treatment market covered in this report is segmented –
1) By Drug Class: Aminosalicylates, Corticosteroids, TNF inhibitors, IL inhibitors, Anti-integrin, JAK inhibitors, Other Drug Classes
2) By Type: Crohn’s Disease, Ulcerative Colitis
3) By Route Of Administration: Oral, Injectable
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Aminosalicylates: Mesalamine, Sulfasalazine, Balsalazide
2) By Corticosteroids: Prednisone, Budesonide, Hydrocortisone
3) By TNF Inhibitors: Infliximab, Adalimumab, Certolizumab pegol
4) By IL Inhibitors: Ustekinumab, Guselkumab
5) By Anti-Integrin: Vedolizumab, Natalizumab
6) By JAK Inhibitors: Tofacitinib, Filgotinib
7) By Other Drug Classes: Antibiotics, Immunosuppressants, Other Novel Therapies
What Trends Are Currently Influencing Growth In The Inflammatory Bowel Disease Treatment Market?
The rise of technology is a significant emerging trend in the treatment market for inflammatory bowel disease. Numerous major firms within the sector are increasingly leveraging AI-centric registries to gain a competitive advantage. For example, Verantos, an RWE firm based in California, launched the Inflammatory Bowel Disease Pragmatic Registry in May 2024, which employs cutting-edge AI to yield high-caliber real-world evidence (RWE) for ulcerative colitis and Crohn’s disease. The purpose of this registry is to aid in the creation of effective treatments by providing a robust dataset, with over 3 billion data points on patient care. This tool assists biopharmaceutical researchers with deep understanding into disease severity, the efficacy of treatments, and clinical outcomes by capitalizing on both structured and unstructured data sourced from electronic health records.
Which Firms Are Considered Leaders In The Inflammatory Bowel Disease Treatment Market Space?
Major companies operating in the inflammatory bowel disease treatment market include AbbVie Inc., Biogen Inc., Johnson & Johnson, Amgen Inc., Advanced Gastroenterology and Surgery Associates P. A., Atlanta Gastroenterology Associates LLC, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Cedars-Sinai Medical Center, Celgene Corporation, Cleveland Clinic Foundation, Digestive Disease Associates of Rockland P. C., Eli Lilly and Company, Gastrointestinal Specialists Inc., Gilead Sciences Inc., GlaxoSmithKline plc, Illinois Gastroenterology Group LLC, The Johns Hopkins Hospital Inc., Massachusetts General Hospital, Mayo Clinic, Merck & Co. Inc., Mount Sinai Health System Inc., Novartis International AG, Pfizer Inc., F. Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited, Texas Digestive Disease Consultants P. A., The Oregon Clinic – Gastroenterology West P. C., Salix Pharmaceuticals Inc., Vifor Pharma AG, Zydus Pharmaceuticals (USA) Inc.
Get The Full Report Here:
What Role Do Regional Policies And Investments Play In Inflammatory Bowel Disease Treatment Market Expansion?
North America was the largest region in the inflammatory bowel disease treatment market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inflammatory bowel disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=6704&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
